BIOG — Biotech Growth Trust Share Price
Last trade - 00:00- £193.85m
- £185.39m
- -£77.53m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.88 | ||
| Price to Tang. Book | 0.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | -2.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.3% | ||
| Return on Equity | -28.38% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 225.51 | -207.29 | -36.18 | 79.72 | -77.53 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +271.12 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
The Biotech Growth Trust PLC is a United Kingdom-based externally managed investment trust. The Company's investment objective is to seek capital appreciation through investment in the biotechnology industry across the world. It invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. The Company invests more than 10%, in aggregate, of the value of its gross assets in other closed-end investment companies (including investment trusts) listed on the London Stock Exchange. The Company invests more than 15% of the value of its gross assets in any one individual stock at the time of acquisition. Its portfolio of investments across various countries includes the Netherlands, the United States of America, Canada, and China. The Company’s alternative investment fund manager is Frostrow Capital LLP.
Directors
- Andrew Joy NEC
- Geoffrey Hsu NED
- Roger Yates NED (63)
- Steven Bates NID (63)
- Julia Blan NID
- Nicola Shepherd NID
- David Willetts NID (65)
- Last Annual
- March 31st, 2025
- Last Interim
- March 31st, 2025
- Incorporated
- May 20th, 1997
- Public Since
- June 23rd, 1997
- Sector
- Collective Investments
- Industry
- Financials
- Exchange
- London Stock Exchange
- Shares in Issue
- 25,915,422
- Address
- 25 Southampton Buildings, LONDON, WC2A 1AL
- Web
- https://www.biotechgt.com/
- Phone
- +44 2030084910
- Auditors
- BDO LLP
Latest News for BIOG
Upcoming Events for BIOG
Biotech Growth Trust PLC Annual Shareholders Meeting
Half Year 2026 Biotech Growth Trust PLC Earnings Release
Similar to BIOG
3i Infrastructure
London Stock Exchange
Aberdeen Asian Income Fund
London Stock Exchange
Aberdeen Equity Income Trust
London Stock Exchange
Aberforth Geared Value & Income Trust
London Stock Exchange
Aberforth Smaller Companies Trust
London Stock Exchange
FAQ
As of Today at 19:36 UTC, shares in Biotech Growth Trust are trading at 748.00p. This share price information is delayed by 15 minutes.
Shares in Biotech Growth Trust last closed at 748.00p and the price had moved by -21.59% over the past 365 days. In terms of relative price strength the Biotech Growth Trust share price has underperformed the FTSE All Share Index by -26.72% over the past year.
The overall consensus recommendation for Biotech Growth Trust is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBiotech Growth Trust does not currently pay a dividend.
Biotech Growth Trust does not currently pay a dividend.
Biotech Growth Trust does not currently pay a dividend.
To buy shares in Biotech Growth Trust you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 748.00p, shares in Biotech Growth Trust had a market capitalisation of £193.85m.
Here are the trading details for Biotech Growth Trust:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: BIOG
Based on an overall assessment of its quality, value and momentum Biotech Growth Trust is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biotech Growth Trust. Over the past six months, its share price has underperformed the FTSE All Share Index by -20.79%.
As of the last closing price of 748.00p, shares in Biotech Growth Trust were trading -11.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biotech Growth Trust PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 748.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biotech Growth Trust's management team is headed by:
- Andrew Joy - NEC
- Geoffrey Hsu - NED
- Roger Yates - NED
- Steven Bates - NID
- Julia Blan - NID
- Nicola Shepherd - NID
- David Willetts - NID